🔥 Portfolio exit news 🔥
🎉 Congratulations to the Ikerian team on being acquired by EssilorLuxottica!
We're thrilled to celebrate this milestone for Ikerian (RetinAI), a company we've been proud to support from the early days on their journey to transform eye health through AI and data-powered solutions.
Founded with a bold vision to harness the power of artificial intelligence and data management in eyecare, Ikerian has built the FDA-cleared and CE-marked RetinAI Discovery platform – a sophisticated solution that applies machine learning and computer vision to support diagnosis and monitoring of critical eye diseases including AMD, glaucoma, and diabetic retinopathy.
Under the leadership of Carlos Ciller and the dedicated team, Ikerian has not only developed cutting-edge technology but has also partnered with pharmaceutical companies and research organizations to accelerate clinical studies and drug development through proprietary real-world evidence.
This acquisition by EssilorLuxottica, a global leader in eyecare and eyewear, represents the perfect next chapter. As Francesco Milleri, Chairman and CEO of EssilorLuxottica noted, RetinAI will add incredible value to their comprehensive, digitally-enabled patient journey ecosystem – turning clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring.
To Carlos, Stefanos, Sandro and the entire Ikerian team: your commitment to improving patient outcomes through innovation has been inspiring to watch. We're excited to see how your technology will now reach patients at a global scale. 🚀